Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022
Intercept Pharmaceuticals (Nasdaq:ICPT) will report its Q4 and full year 2021 financial results before market opens on March 2, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intercept Pharmaceuticals (Nasdaq:ICPT) will report its Q4 and full year 2021 financial results before market opens on March 2, 2022. Following the announcement, an 8:30 a.m. ET conference call will be hosted by the management team to discuss the results. The call can be accessed on the investor page of their website or by calling a designated number. Intercept focuses on developing therapeutics for progressive liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis.
Details
News Market Reaction – ICPT
The recorded move for ICPT in the trading session of this news was -5.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2021 financial results prior to market open on Wednesday, March 2, 2022. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.
The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free) passcode 3258502. Archived webcasts will be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
CONTACT
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.